Top of this page
Skip navigation, go straight to the content

ucb-usa.com Newsroom UCB U.S. News

Categories

  • UCB Announces New Data from its Epilepsy Portfolio Presented on the American Academy of Neurology Virtual Platform

    UCB_LOGO_1280x960
    Six poster presentations highlight clinical data on NAYZILAM® (midazolam) nasal spray CIV and BRIVIACT® (brivaracetam) CV in addition to epilepsy-related health economics outcomes research

    Atlanta, Ga., June 24, 2020: UCB today announced six posters selected for presentation at the 72nd American Academy of Neurology (AAN) annual meeting, available online via the 2020 AAN Science Highlights virtual platform, which replaced the in-person event previously cancelled due to the COVID-19 pandemic. The abstracts were also published in the online supplement to Neurology.

    Read more

  • Like
  • Press Release: UCB Presents New Data Demonstrating Commitment to Epilepsy at 2019 American Epilepsy Society Meeting

    UCB_LOGO_1280x960
    • 14 scientific presentations will cover UCB’s pipeline assets, epilepsy-specific research, and licensed medicines, including NAYZILAM, now available for the acute treatment of seizure clusters in epilepsy patients 12 years of age and older
    • Friday evening symposium on “Epilepsy Treatment Update for Patients Suffering from Seizure Clusters” includes Epilepsy Foundation’s project on seizure emergencies and a panel discussion on the misconceptions around seizure clusters

    Read more

  • Like
  • Press Release: UCB announces BRIVIACT® (brivaracetam) now approved by FDA to treat partial-onset (focal) seizures in pediatric epilepsy patients

    Briviact_1280x960_Logo

    • BRIVIACT® (brivaracetam) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures.
    • Approval provides pediatric epilepsy patients a treatment option which can be initiated at a therapeutic dose from day one.
    • Pediatric epilepsy is the most common, serious neurological disorder among children and young adults, thought to affect nearly 470,000 children in the U.S.,1, 2
    • Indication comes less than 2 years after the launch of BRIVIACT in the U.S., building on existing adult monotherapy and adjunctive therapy indications, and broadening clinical application for UCB’s newest anti-epilepsy drug.


    Read more

  • Like